RBC Capital Maintains Outperform on Medline, Lowers Price Target to $46

Benzinga Newsdesk www.benzinga.com Negative 94.8%

Neg 94.8% Neu 0% Pos 0%

RBC Capital analyst Ryan Halsted maintains Medline (NASDAQ:MDLN) with a Outperform and lowers the price target from $53 to $46.